Equal benefits to our residential courses, without the travel.View Courses
All our courses. 12 months access. One flat fee.More Information
Non-members can signup to keep up to date with RQA news and events.Add your details now
7th October 2020
EMA’s human medicines committee (CHMP) has started the first ‘rolling review’ of a COVID-19 vaccine, which is being developed by the company AstraZeneca in collaboration with the University of Oxford.
The start of the rolling review means that the committee has started evaluating the first batch of data on the vaccine, which come from laboratory studies (non-clinical data). This does not mean that a conclusion can be reached yet on the vaccine’s safety and effectiveness, as much of the evidence is still to be submitted to the committee.